Last reviewed · How we verify
Tenecteplase thrombolysis
Tenecteplase thrombolysis is a Fibrinolytic agent / Thrombolytic Small molecule drug developed by Xuanwu Hospital, Beijing. It is currently FDA-approved for Acute myocardial infarction, Acute ischemic stroke. Also known as: rhTNK-tPA.
Tenecteplase is a fibrin-specific thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots by breaking down fibrin.
Tenecteplase is an exogenous protein used as an enzyme to activate tissue-type plasminogen activator, which is involved in the breakdown of blood clots. It is indicated for the treatment of conditions such as stroke, ischemic stroke, and cerebrovascular disorders, typically administered through intra-arterial injection or other methods.
At a glance
| Generic name | Tenecteplase thrombolysis |
|---|---|
| Also known as | rhTNK-tPA |
| Sponsor | Xuanwu Hospital, Beijing |
| Drug class | Fibrinolytic agent / Thrombolytic |
| Target | Fibrin; Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Tenecteplase is a genetically engineered variant of tissue plasminogen activator (tPA) with enhanced fibrin specificity and longer half-life. It binds to fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which degrades the fibrin matrix of blood clots. This mechanism enables rapid thrombolysis in acute thrombotic conditions such as acute myocardial infarction and acute ischemic stroke.
Approved indications
- Acute myocardial infarction
- Acute ischemic stroke
Common side effects
- Bleeding (major and minor)
- Intracranial hemorrhage
- Hypotension
- Arrhythmias
Key clinical trials
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO) (PHASE3)
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenecteplase thrombolysis CI brief — competitive landscape report
- Tenecteplase thrombolysis updates RSS · CI watch RSS
- Xuanwu Hospital, Beijing portfolio CI
Frequently asked questions about Tenecteplase thrombolysis
What is Tenecteplase thrombolysis?
How does Tenecteplase thrombolysis work?
What is Tenecteplase thrombolysis used for?
Who makes Tenecteplase thrombolysis?
Is Tenecteplase thrombolysis also known as anything else?
What drug class is Tenecteplase thrombolysis in?
What development phase is Tenecteplase thrombolysis in?
What are the side effects of Tenecteplase thrombolysis?
What does Tenecteplase thrombolysis target?
Related
- Drug class: All Fibrinolytic agent / Thrombolytic drugs
- Target: All drugs targeting Fibrin; Plasminogen
- Manufacturer: Xuanwu Hospital, Beijing — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute myocardial infarction
- Indication: Drugs for Acute ischemic stroke
- Also known as: rhTNK-tPA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing